Dr. Wenan Qiang will serve as a co-Investigator on this project. Dr. Qiang will be responsible for overseeing the development of Patient-Derived Xenograft (PDX) tumor models of hepatocellular carcinoma. Dr. Qiang will also design and administer therapeutic efficacy studies using subcutaneous models of liver PDX to evaluate the test article ABL kinase inhibitor. He will work closely with Dr. Qiu to design and analyze experiments to advance the project’s goals.
|Effective start/end date||7/1/18 → 6/30/22|
- Loyola University Chicago (LU 209133//RSG-18-107-01-TBG)
- American Cancer Society (LU 209133//RSG-18-107-01-TBG)